REGENXBIO for REGENXBIO
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislative proposals contained in year end Omnibus Appropriations Bill (H.R. 2617) including certain unenacted PDUFA "riders" such as clinical trial diversity and the FDA accelerated approval program.(H.R. 6696 and H.R. 6963.) In addition, provisions in the omnibus bill related to the funding of newborn screening programs as well as the enactment of a National Academy of Medicine study of NBS. Continued work on Value Based Agreement (VBA) legislation, H.R.7389, introduced by Reps. Schrader, Guthrie and Mullin on 4/4/22.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRUCE ARTIM | Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06) |
Trade (domestic/foreign) TRD
Proposed Covid-19 IP waivers under consideration by the U.S. Congress, Biden Administration, World Health Organization and World Trade Organization, including proposals to expand the waiver beyond vaccines to therapeutics and diagnostic products. Retention of 12 years of regulatory data protection for biologics in international trade agreements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRUCE ARTIM | Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06) |
Copyright/Patent/Trademark CPT
Reform of Section 101 of the patent code including the Patent Eligibility Restoration Act, S. 4734. IP issues related to the enactment of the drug pricing provisions of the IRA including the so-called "9/13 years, drugs/biologics and orphan drug-related provisions. S.1435/H.R. 2873/H.R. 2884 (patent thickening/product hopping) S.1425/H.R. 2883 (citizen petitions) S.1428/H.R.2891 (Rx patent settlements) Leahy-Cornyn Restoring the America Invents Act, PTAB reform bill. S.4430, Interagency Patent Coordination and Improvement Act of 2022 introduced by Sens. Durbin, Tillis, and Grassley.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRUCE ARTIM | Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06) |
Immigration IMM
Monitoring for proposed changes in immigration laws affecting non-U.S. citizen scientists and their families.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRUCE ARTIM | Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06) |
Taxation/Internal Revenue Code TAX
Legislative proposals to reinstate direct expensing of R&D investment such as considered but not included in the year end Omnibus Appropriations bill, H.R.2167.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRUCE ARTIM | Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.